Literature DB >> 9616745

Hormone replacement therapy increases the risk of breast cancer.

G A Colditz1.   

Abstract

Established risk factors for breast cancer predominantly act through hormonal pathways. The major exceptions are (1) family history, which accounts for approximately 6 percent of the cases of breast cancer in the United States, (2) radiation, particularly in adolescence, which accounts for a small fraction of all cases of breast cancer, and (3) personal history of benign breast disease, which may include precursor lesions in the pathway to breast cancer. Age at menarche, parity, and age at first birth, as well as age at menopause are related to risk of breast cancer. In addition, among postmenopausal women, relative weight and use of postmenopausal hormones increase risk of breast cancer. This paper reviews the evidence that these factors may act through hormonal pathways or cell division in response to cyclic hormonal levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9616745     DOI: 10.1111/j.1749-6632.1997.tb48598.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.

Authors:  Z J Zhai; H W Li; G W Liu; X H Qu; B Tian; W Yan; Z Lin; T T Tang; A Qin; K R Dai
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Breast cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.

Authors:  Swann Arp Adams; James R Hebert; Susan Bolick-Aldrich; Virginie G Daguise; Catishia M Mosley; Mary V Modayil; Sondra H Berger; Jane Teas; Michael Mitas; Joan E Cunningham; Susan E Steck; James Burch; William M Butler; Marie-Josephe D Horner; Heather M Brandt
Journal:  J S C Med Assoc       Date:  2006-08

3.  Noninvasive functional optical spectroscopy of human breast tissue.

Authors:  N Shah; A Cerussi; C Eker; J Espinoza; J Butler; J Fishkin; R Hornung; B Tromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

4.  LC-MS-based plasma metabolomics reveals metabolic variations in ovariectomy-induced osteoporosis in female Wistar rats.

Authors:  Yan Hu; Xiaojian Zhang; Yu Shan
Journal:  RSC Adv       Date:  2018-07-11       Impact factor: 4.036

5.  Metastatic phenotype is regulated by estrogen in thyroid cells.

Authors:  Shilpi Rajoria; Robert Suriano; Arulkumaran Shanmugam; Yushan Lisa Wilson; Stimson P Schantz; Jan Geliebter; Raj K Tiwari
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

6.  Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo.

Authors:  Shuai Chen; Gu Jin; Kang-Mao Huang; Jian-Jun Ma; Qiang Wang; Yan Ma; Xiao-Zhen Tang; Zhi-Jie Zhou; Zhi-Jun Hu; Ji-Ying Wang; An Qin; Shun-Wu Fan
Journal:  Sci Rep       Date:  2015-08-04       Impact factor: 4.379

7.  Effects of remifemin treatment on bone integrity and remodeling in rats with ovariectomy-induced osteoporosis.

Authors:  Guangxia Cui; Huijie Leng; Ke Wang; Jianwei Wang; Sainan Zhu; Jing Jia; Xing Chen; Weiguang Zhang; Lihua Qin; Wenpei Bai
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.